Please turn JavaScript on
Life Sciences Voice icon

Life Sciences Voice

Subscribe in seconds and receive Life Sciences Voice's news feed updates in your inbox, on your phone or even read them from your own news page here on follow.it.

You can select the updates using tags or topics and you can add as many websites to your feed as you like.

And the service is entirely free!

Follow Life Sciences Voice: Lifescivoice - News and Insights of Life Sciences Industry

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  2.12 / day

Message History

Executive Summary

Omnichannel engagement has become one of the most important strategic priorities across healthcare, pharmaceuticals, medical technology, and life sciences organizations. The goal is straightforward: create seamless, personalized, and consistent interactions across every touchpoint where healthcare professionals (HCPs), patients, caregivers, and stakeh...


Read full story

After the FDA’s tough stance on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market, Fulcrum Therapeutics has dropped its only clinical-stage program.

In March, Ipsen pulled Tazverik from all indications and markets, citing a data moni...


Read full story

Radiology departments at hospitals continue to face significant capacity constraints, while imaging procedures often remain a frustrating experience for patients. Health systems and imaging centers are managing growing demand for medical scans despite aging equipment and li...


Read full story

Cingulate has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for CTx-1301, its investigational treatment for attention-deficit/hyperactivity disorder (ADHD), after submitting its application to the agency in July of last year.

The Kansas City-based drug developer said the


Read full story

Abivax reported phase 3 maintenance data showing that its experimental oral ulcerative colitis treatment, obefazimod, achieved clinical remission rates above those seen with placebo, while also reporting several cancer cases among patients receiving the hi...


Read full story